Retinoblastoma Loss in Cancer: Casting a Wider Net.

Choudhury, Atish D; Beltran, Himisha · Clin Cancer Res · 2019

editorial · Level V

Where this comes from

Abstract

Capturing both genomic and nongenomic mechanisms of retinoblastoma gene dysfunction has potential to improve risk stratification and patient selection for biomarker-driven therapy. A 186-gene expression signature is capable of identifying Rb loss across cancer types, providing a new framework for assessing Rb dysfunction based on transcriptome data.<i>See related article by Chen et al., p. 4290</i>.

Medical subject headings